Updated May 30, 2026, 4:23 PM
AntifungalUS FDA Database Verified

amphotericin B liposomal (LAmB)

Generic: Amphotericin B liposomal

Brand: AmBisome

(am-fore- ter'-i- sin)

Pregnancy Category: B

Pharmacological Action

Increases cell membrane permeability in susceptible fungi by binding to membrane sterols; alters cell membrane, thereby causing leakage of cell components, cell death

Therapeutic outcome: Resolution of infection

Uses

Empirical therapy for presumed fungal infection in febrile neutropenic patients; treatment of Cryptococcal Meningitis in HIV- infected patients; treatment of Aspergillus, Candida, and/or Cryptococcus infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate (Aspergillus flavus, Aspergillus fumigatus, Blastomyces dermatitidis, Candida albicans, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans); treatment of visceral leishmaniasis Unlabeled uses: Coccidiomycosis, histoplasmosis

Contraindications

Hypersensitivity

Precautions: Anemia, breastfeeding, cardiac disease, children, electrolyte imbalance, geriatric, hematological/hepatic/renal disease, hypotension, pregnancy (B), severe bone marrow depression

Dosage & Routes

Visceral leishmaniasis Adult and child \geq 1 mo: IV 3 mg/kg every 24 hr days 1-5, and days 14, 21 (immunocompetent), 4 mg/kg every 24 hr days 1-5, and days 10, 17, 24, 31, 38 (immunocompromised) Cryptococcal meningitis in HIV Adult and child \geq 1 mo: IV 6 mg/kg/day Fungal infection, empirical Adult and child \geq 1 mo: IV 3 mg/kg/day Fungal infection, systemic Adult and child \geq 1 mo: IV 3- 5 mg/kg/day

Available forms: Powder for inj 50- mg vial

Implementation Do not confuse four different types; these are not interchangeable: conventional amphotericin B, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome May premedicate with acetaminophen, diphenhydrAMINE

IV route: Give only after C&S confirms organism, product needed to treat condition; make sure product is used for life- threatening infections Administer by IV infusion only; handle with aseptic technique as LAmB does not contain any preservatives Visually inspect products for particulate matter and discoloration

Reconstitution: LAmB must be reconstituted using sterile water for injection (without a bacteriostatic agent); do not reconstitute with saline or add saline to the reconstituted suspension, do not mix with other drugs; doing so can cause a precipitate to form Reconstitute vials containing 50 mg of LAmB/12 ml of sterile water (4 mg/ml) Immediately after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 sec; the suspension should be yellow and translucent; visually inspect vial for particulate matter and continue shaking until product is completely dispersed Store suspension for up to 24 hours refrigerated if using sterile water for injection; do not freeze Filtration and dilution: Calculate the amount of reconstituted (4 mg/ml) suspension to be further diluted and withdraw this amount into a sterile syringe Attach the provided 5- micron filter to the syringe; inject the syringe contents through the filter, into the appropriate amount of D_5 W injection; use only one filter per vial The suspension must be diluted with D_5 W injection to a final concentration of 1- 2 mg/ml before administration; for infants and small children, lower concentrations (0.2- 0.5 mg/ml) may be appropriate to provide sufficient volume for infusion Use injection of LAmB within 6 hr of dilution with D_5 W IV

INF: Flush intravenous line with D_5 W injection before infusion; if this cannot be done, then a separate IV line must be used An inline membrane filter may be used provided the mean pore diameter of the filter is not less than 1 micron Administer by IV infusion using a controlled infusion device over a period of approximately 120 min; infusion time may be reduced to approximately 60 min in patients who tolerate the infusion; if discomfort occurs during infusion, the duration of infusion may be increased Acetaminophen and diphenhydrAMINE 30 min before inf to reduce fever, chills, headache Store protected from moisture and light; diluted solution is stable for 24 hr at room temp

Y- site compatibilities: Acyclovir, amifostine, aminophylline, anidulafungin, atropine, azithromycin, bivalirudin, bumetanide, buprenorphine, busulfan, butorphanol, CARBO- platin, carmustine, ceFAZolin, ceFOXitin, ceftozime, ceftRIXone, cefuroxime, cimetidine, clindamycin, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, diphenhydrAMINE, doxacurium, enalaprilat, ePHEDrine, EPINEPHrine, eptifibatide, ertapenem, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fludarabine, fluorouracil, fosfemytoin, furosemide, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, ifosfamide, isoproterenol, ketorolac, levorphanol, lidocaine, linezolid, mesna, methotrexate, methylPREDNISolone, metoprolol, milrinone, mitoMYcin, nesiritide, nitroglycerin, nitroprusside, octreotide, oxaliplatin, oxytocin, palonosetron, pancuronium, pantoprazole, PEMEtrexed, PENTobarbital, PHENobarbital, phenylephrine, piperacillin/tazobactam, potassium chloride, procainamide, ranitidine, SUFentanil, tacrolimus, theophylline, thiopental, thiotepa, ticarcillin/clavulanate, tigecycline, trimethoprim- sulfamethoxazole, vasopressin, vinCRISTine, voriconazole, zidovudine

Adverse Effects

CNS: Headache, fever, chills, peripheral nerve pain, paresthesias, peripheral neuropathy, seizures, dizziness, insomnia

CV: Bradycardia, hypotension, cardiac arrest

EENT: Tinnitus, deafness, diplopia, blurred vision

ENDO: Hyperglycemia

GI: Nausea, vomiting, anorexia, diarrhea, cramps, hemorrhagic gastroenteritis, acute liver failure

GU: Hypokalemia, azotemia, hyposthenuria, renal tubular acidosis, nephrocalcinosis, permanent renal impairment, anuria, oliguria

HEMA: Normochromic normocytic anemia, thrombocytopenia, agranulocytosis, leukopenia, eosinophilia, hyponatremia, hypomagnesemia

INTEG: Burning, irritation, pain, necrosis at inj site with extravasation, flushing, dermatitis, skin rash (topical route)

MS: Arthralgia, myalgia, generalized pain, weakness, weight loss

RESP: Dyspnea

SYST: Stevens- Johnson syndrome, toxic epidermal neurolysis, exfoliative dermatitis, anaphylaxis

Pharmacokinetics

Absorption: Complete bioavailability (IV)

Distribution: Body tissues

Metabolism: Liver

Excretion: Kidneys, detectable for several weeks

Half-life: Liposomal mean 4-6 days

Pharmacodynamics

Onset: Immediate

Peak: 1-2 hr

Duration: Unknown

Interactions

Individual drugs

Digoxin: increased hypokalemia

Drug classifications Other nephrotoxic antibiotics (aminoglycosides, CISplatin, vancomycin, cycloSPORINE, polymyxin B): increased nephrotoxicity Corticosteroids, skeletal muscle relaxants, thiazides: increased hypokalemia

Nursing Considerations

Assessment VS every 15- 30 min during first inf; note changes in pulse, B/P • I&O ratio; watch for decreasing urinary output, change in specific gravity; discontinue product to prevent permanent damage to renal tubules • Blood studies: CBC, potassium, sodium, calcium, magnesium every 2 wk, BUN, creatinine 2- 3 X/wk • Weight weekly; if weight increases by more than 2 lb/wk, edema is present; renal damage should be considered • For renal toxicity: increasing BUN, serum creatinine; if BUN is .40 mg/dl or if serum creatinine is .3 mg/dl, product may be discontinued, dosage reduced • For hepatotoxicity: increasing AST, ALT, alk phos, bilirubin, monitor LFTs • For allergic reaction: dermatitis, rash; product should be discontinued, antihistamines (mild reaction) or EPINEPHrine (severe reaction) administered • For hypokalemia: anorexia, drowsiness, weakness, decreased reflexes, dizziness, increased urinary output, increased thirst, paresthesias • For ototoxicity: tinnitus (ringing, roaring in ears), vertigo, loss of hearing (rare) • For infusion reaction: chills, fever, pain, swelling at site

Patient/family education Teach patient that long- term therapy may be needed to clear infection (2 wk- 3 mo, depending on type of infection) Instruct patient to notify prescriber of bleeding, bruising, or soft- tissue swelling

Evaluation

Positive therapeutic outcome: Decreased fever, malaise, rash; negative C&S for infecting organism

Reference

Mosby's Drug Guide; Davis Drug Guide

Need clinical tools for this drug?

Save notes, bookmark this drug, and run formula method (desire over have) dosage calculations all inside the KosPharm Dashboard.

One-time payment. No subscription. No recurring charges.

Sign in to Get Full Access